SEC recommends phase 1 clinical trials of Reliance’s 2-dose Covid-19 vaccine

 SEC recommends phase 1 clinical trials of Reliance's 2-dose Covid-19 vaccine

The Subject Expert Committee (SEC) has recommended phase 1 clinical trials of Reliance Life Sciences’ vaccine candidate against the coronavirus disease (Covid-19), press agency ANI reported on Friday. The proposed vaccine candidate comprises two doses, and is predicated on recombinant protein platform, as per reports.

Now that the SEC has recommended phase 1 trials, subsequent step for Reliance Life Sciences is to receive approval from the Drugs Controller General India (DCGI). Once the country’s top drugs regulator grants permission, the corporate can begin the primary phase of clinical trials for its vaccine candidate.

Also Read | Zydus vaccine for teenagers likely to be available by Oct, says Centre

While Reliance Sciences itself may be a testing centre for Covid-19, the exercise are going to be conducted at 10 sites, including those in in Delhi, Maharashtra, Tamil Nadu and Andhra Pradesh . Phase 1 lasts for nearly two months, or 58 days, and is conducted to detect the very best number of doses that the majority patients can tolerate.

The DCGI has so far granted Emergency Use Authorisation (EUA) to 6 vaccines, of which two are indigenous while the remainder are foreign-made. Covaxin and Covishield were the primary two shots to receive EUA, followed by Sputnik V, Moderna, Johnson & Johnson and ZyCoV-D respectively. Among these, Covaxin and ZyCoV-D are made in India vaccines.

The nationwide vaccination drive against Covid-19 began on January 16 and each citizen above the age of 18 is eligible to be inoculated. Till now, 612,208,542 doses are administered across the country, including 7,948,349 within the last 24 hours, as per the Union health ministry’s dashboard.

Also Read | India has administered a minimum of 610 million Covid vaccine doses till now

Reliance Life Sciences describes itself as a research-driven organisation developing business opportunities in bio-therapeutics, pharmaceuticals, clinical research, molecular medicine etc. because the name suggests, it comes under the Promoter Group of Mukesh Ambani’s Reliance Industries Limited (RIL).

Previous Post Next Post